Information Provided By: 
Fly News Breaks for January 22, 2016
BMY
Jan 22, 2016 | 06:31 EDT
Leerink analyst Seamus Fernandez recommends buying shares of Bristol-Myers now saying the company's dominance of the immuno-oncology market "is likely to continue for at least the next several years." The analyst expects Bristol to see "substantial operating leverage" in the second half of 2016 as the company annualizes the loss of Abilify profits. He raised his price target for the shares to $78 from $77 and keeps an Outperform rating on the name.
News For BMY From the Last 2 Days
There are no results for your query BMY
